✦ LIBER ✦

High-Intensity Intravenous Cyclophosphamide and Cisplatin, Interim Surgical Debulking, and Intraperitoneal Cisplatin in Advanced Ovarian Carcinoma: A Pilot Trial with Ten-Year Follow-up

✍ Scribed by Fred Shapiro; Jeffrey Schneider; Maurie Markman; Bonnie S. Reichman; Ennapadam Venkatraman; Richard Barakat; Lois Almadrones; David Spriggs

Book ID: 112247208
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 87 KB
Volume: 67
Category: Article
ISSN: 0090-8258
DOI: 10.1006/gyno.1997.4821

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Ten-year results of a randomised trial c

Ten-year results of a randomised trial comparing cisplatin with cisplatin and cyclophosphamide in advanced, suboptimally debulked ovarian cancer

✍ C Marth; C Tropé; I.B Vergote; G.B Kristensen 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 127 KB

Phase II Trial of Intraperitoneal Cispla

Phase II Trial of Intraperitoneal Cisplatin with Intravenous Doxorubicin and Cyclophosphamide in Previously Untreated Patients with Advanced Ovarian Cancer—Long-Term Follow-Up

✍ Robert J. Morgan Jr.; Patricia Braly; Gary Cecchi; Lucille Leong; Stephen Shibat 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 65 KB

Ten-year follow-up of a phase 2 study of

Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer

✍ Gisele A. Sarosy; Mahrukh M. Hussain; Michael V. Seiden; Arlan F. Fuller; Najmos 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 1 views

## Abstract ## BACKGROUND: The objective of this study was to assess activity and toxicity in patients with newly diagnosed, advanced‐stage epithelial ovarian cancer (EOC) who were receiving dose‐intense paclitaxel, cyclophosphamide, cisplatin, and filgrastim delivered with a flexible dosing sched